Home › Endometrial Cancer › Illinois
Endometrial Cancer clinical trials in Illinois
38 studies for Endometrial Cancer are looking for participants at sites in Illinois.
Cities in Illinois
- Chicago25 studies
- Champaign6 studies
- Evanston6 studies
- Peoria6 studies
- Cicero4 studies
- Danville3 studies
- Bloomington3 studies
- Charleston3 studies
- Decatur3 studies
- Waukegan3 studies
- Joliet3 studies
- Aurora3 studies
- Naperville3 studies
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Advocate Good Shepherd Hospital, Barrington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- and 57 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT05950464Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- and 26 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- University of Illinois Cancer Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- University of Chicago, Chicago
RecruitingObservational study
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05051722Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Carle at The Riverfront, Danville
- Carle Physician Group-Effingham, Effingham
- Carle Physician Group-Mattoon/Charleston, Mattoon
- and 3 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601DESTINY-PANTUMOUR04
- Research Site, Decatur
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago Medical Center, Chicago
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Northwestern University, Chicago
- Northwestern Medicine Orland Park, Orland Park
- Northwestern Medicine Cancer Center Warrenville, Warrenville
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT05640999Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Northwestern University Feinberg School of Medicine, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- University of Chicago Medical Center ( Site 5002), Chicago
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07109726A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- OSF Saint Francis Medical Center, Peoria
- Carle Cancer Institute, Urbana
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT06340568Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- City of Hope - Chicago, Zion
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Endeavor Health NorthShore, Evanston
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Arlington Heights
- Research Site, Evanston
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06989112Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- University of Chicago Medical Center, Chicago
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Northwestern Medicine, Chicago
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Chicago Medical Center, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- St. Francis Medical Center (OSF Healthcare), Peoria
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07470853A Study of PHST001 in Advanced Solid Tumors
- University of Chicago Medical Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06840886Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- St. Francis Medical Center (OSF Healthcare), Peoria
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07444814A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06330064A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Hope and Healing Cancer Services, Hinsdale
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Chicago
- Research Site, Peoria
- Research Site, Urbana
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Northwestern University, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- The University of Chicago Medical Center (UCMC), Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- Northwestern Memorial Hospital, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04300556Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
- Northwestern University, Chicago
Recruiting
Ages 60 and older · Women · Updated May 29, 2026 · NCT05743517A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- University of Chicago Medical Center, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
- Northwestern Memorial Hospital, Chicago
Recruiting
Ages 18 and older · Women · Updated Mar 24, 2026 · NCT05990426A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Kellogg Cancer Center, Evanston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 80 · Women · Updated Feb 28, 2025 · NCT00005095Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Dr. Sudarshan K. Sharma, Ltd., Hinsdale
RecruitingPhase 2/3
Ages 18 and older · Women · Updated May 2, 2024 · NCT05797831From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.